NCM · Biotechnology

INAB (INAB) Stock

$1.19 -0.83% NCM: INAB Healthcare

Valuation

MetricValue
Price$1.19
Market Cap$11.41M
P/E Ratio-0.35
P/B Ratio0.26
P/S Ratio0.00
EPS (TTM)$-4.44
52-Week High$2.73
52-Week Low$1.17
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-67.86%
ROA-59.37%
ROCE-74.07%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.10
Current Ratio9.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-15.0M$-29.0M$-30.0M$-30.0M$-20.0M
Net Profit$-15.0M$-29.0M$-30.0M$-30.0M$-19.0M
EPS$-0.78$-1.36$-1.00$-0.57$-4.44
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$42.0M$33.0M$34.0M$21.0M$32.0M
Total Liabilities$4.0M$10.0M$9.0M$6.0M$5.0M
Cash$37.0M$18.0M$21.0M$11.0M$27.0M
Borrowings$2.0M$6.0M$5.0M$5.0M$3.0M

Latest News

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma GlobeNewswire · Jul 9, 2026 IN8bio (INAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Zacks · Jun 4, 2026 IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies GlobeNewswire · Jun 3, 2026 IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 GlobeNewswire · Jun 1, 2026 IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma GlobeNewswire · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-24.0M$-23.0M$-24.0M$-13.0M
Investing Cash Flow$-1.0M$-7.0M$-1.0M$0$0
Financing Cash Flow$-3.0M$0$0$5.0M$0
Net Cash Flow$19.0M$-19.0M$3.0M$-10.0M$16.0M
Free Cash Flow$-14.0M$-28.0M$-24.0M$-24.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-199.88%
Quick Ratio10.50
Interest Coverage—
Return 1Y-33.49%
Return 3Y-97.04%
Return 5Y—

Ownership

Insiders Held13.40%
Institutions Held38.11%
Institutions Float Held44.01%
Institutional HolderSharesReport Date
Alyeska Investment Group, L.p.944,3192026-03-31
Franklin Resources, Inc.914,5312026-03-31
683 Capital Management LLC724,6372026-03-31
Stonepine Capital Management, LLC663,4122026-03-31
Bios Capital Management, LP 167,8052026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXP $1.40 -1.40% -0.36 $2.22M 0.00%
APRE $0.62 -1.16% -0.47 $4.06M 0.00%
APVO $4.21 -4.10% -0.06 $9.21M 0.00%
BCDABioCardia, Inc. $0.84 -1.11% -0.83 $4.88M 0.00%
GLTODamora Therapeutics, Inc. $21.58 -3.36% -0.17 $34.47M 0.00%

About INAB

INAB is led by CEO Tai-Wei, employs 18 people, headquartered in US, publicly traded since 2021.

INAB stock trades at $1.19 with a market capitalization of $11.41M. The stock is valued at a price-to-earnings (P/E) ratio of -0.35, price-to-book of 0.26, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.17 and $2.73, and currently trades 56.4% below its 52-week high.

On profitability, INAB generates a return on equity (ROE) of -67.86%, return on capital employed of -74.07%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides